Treatment Naïve Wet AMD

Sponsor: OTX SOL-R – Wet AMD

Current medications for wet macular degeneration are very effective in treating and stabilizing the condition. However, where they often fall short is how long they last in the eye. This leads to the need for frequent re-treatment in order to maintain stability. In the current enrolling SOL-R trial, we are looking for patients with newly diagnosed wet AMD or have received minimal clinical injections in the last 4 months. In the study, patients would either receive current standard of care intravitreal injection treatments vs. intravitreal injection of a sustained release implant that slowly dissolves and releases medication over time. Initial studies have shown efficacy of the implants over six months with sustained efficacy, reduced rate of retreatment, and a comparable safety profile to current standard of care treatments.

For more information, please reach out to one of our clinical coordinators.